Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61988987%3A17110%2F17%3AA1801R50" target="_blank" >RIV/61988987:17110/17:A1801R50 - isvavai.cz</a>
Alternative codes found
RIV/00843989:_____/17:E0106620
Result on the web
<a href="http://dx.doi.org/10.1016/S1470-2045(17)30578-8" target="_blank" >http://dx.doi.org/10.1016/S1470-2045(17)30578-8</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/S1470-2045(17)30578-8" target="_blank" >10.1016/S1470-2045(17)30578-8</a>
Alternative languages
Result language
angličtina
Original language name
Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial
Original language description
Background The phase 3 ENDEAVOR trial was a head-to-head comparison of two proteasome inhibitors in patients with relapsed or refractory multiple myeloma. Progression-free survival was previously reported to be significantly longer with carfilzomib administered in combination with dexamethasone than with bortezomib and dexamethasone in an interim analysis. The aim of this second interim analysis was to compare overall survival between the two treatment groups. Interpretation Carfilzomib provided a significant and clinically meaningful reduction in the risk of death compared with bortezomib. To our knowledge, carfilzomib is the first and only multiple myeloma treatment that extends overall survival in the relapsed setting over the current standard of care. This study is informative for deciding which proteasome inhibitor to use for treating this disease.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30205 - Hematology
Result continuities
Project
—
Continuities
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Others
Publication year
2017
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
LANCET ONCOLOGY
ISSN
1470-2045
e-ISSN
1474-5488
Volume of the periodical
18
Issue of the periodical within the volume
10
Country of publishing house
US - UNITED STATES
Number of pages
11
Pages from-to
1327-1337
UT code for WoS article
000411843500049
EID of the result in the Scopus database
2-s2.0-85028079883